Soon a new cGMP grade plasmid DNA biomanufacturing unit at RD-Biotech!
RD-BIOTECH will complete its biomanufacturing offer with a new plasmid DNA production unit, raw materials for innovative therapies (RNA vaccines, therapeutic mRNA, CAR-T cells, viral vectors, etc.)
These new cGMP-grade plasmid DNA biomanufacturing facilities will complement our current R&D-grade and “GMP-like” (High Quality Grade) pDNA bioproduction capabilities.
See you soon for a new episode! Follow with us the progress of the construction site
RD-Biotech celebrates ONE year in its new facilities!
It's been a year since we moved into our new laboratories: A stimulating work environment, an experimented and dynamic team, quality laboratories & equipment! All the conditions are met to provide the best service, adapted to your needs.
Biomanufacturing of plasmids, antibodies, proteins or cells - Development of your biological tools - Do not hesitate to contact us!
From strain engineering to the expression of your recombinant protein!
RD-Biotech will present the fully comprehensive platform "From the engineering of the bacterial strain to the expression of your recombinant protein" at the "Cell Factories for Industrial Bioproduction" congress organized by ADEBIOTECH, March 29 and 30, 2022 at Biocitech, Romainville (Fr). This innovative service combines the expertise in microbiology of Smaltis, a company of the mAbexperts group, with the the well known expertise of RD-Biotech in DNA vector construction and recombinant proteins production. Come meet us on our booth https://asso.adebiotech.org/colloques/cell-factories-for-industrial-bioproduction/
RD-Biotech, a complete platform from DNA to antibody
For your antibody development projects, for applications in immunotherapy, diagnostics, research: contact our team of experts in molecular biology and antibody engineering: Contact us for more information!
RD-Biotech: laureate “France Relance, volet Résilience”
On Thursday 30 September 2021, RD-Biotech was pleased to welcome Mr Jean-François Colombet, Prefect of the Doubs, as part of the France Relance plan, Résilience category.
Selected by the French government as part of the France Relance plan, the project to build a GMP-grade production unit will complement our current R&D grade and "High Quality Grade" ("GMP like") plasmid DNA biomanufacturing capacities, in order to answer the growing of market demand in new therapies. Construction will soon begin on the Temis Santé site
Link to the article: RD-Biotech: lauréat sur le volet Résilience - santé
RD-Biotech is here to help you in your projects related to Covid-19!
Development / Production of monoclonal or recombinant antibodies - Expression vector construction - Antigen expression - DNA plasmid production...: Contact us for more information!